Silver Encapsulated Magnetic Nanoparticles for Pathogen Inactivation in Platelets

银封装磁性纳米粒子用于灭活血小板中的病原体

• 批准号: 7325661
• 负责人: SEASON S-S WONG
• 金额: $ 14.54万
• 依托单位: LYNNTECH, INC.
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-15 至 2008-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7325661
• 关键词: Address; Adopted; Aerobic; Aerobic Bacteria; Affect; Alloys; American; Americas; Anaerobic Bacteria; Area; Award; Bacteria; Biochemical; Biochemistry; Biological; Biological Assay; Blood; Blood Banks; Blood Platelets; Blood donor; Burn Trauma; Businesses; Canada; Cancer Center; Cancer Patient; Capital; Carbon; Catalysis; Cells; Centers for Disease Control and Prevention (U.S.); Cessation of life; Chemicals; Chemistry; Client; Clinical; Collaborations; Collection; Communities; Compatible; Computers; Contractor; Data; Decontamination; Detection; Detergents; Development; Devices; Disinfection; Doctor of Medicine; Donor Selection; Dose; Economics; Educational workshop; Electronics; Emerging Technologies; Encapsulated; Ensure; Equipment; Equipment and Supplies; Equipment and supply inventories; Erythrocytes; Europe; Evaluation; Excision; Experimental Designs; Fever; Foy; Frequencies; General Population; Genetic; Goals; Government; Gram-Positive Bacteria; Grant; Growth; HIV Infections; Health; Healthcare Systems; Hepatitis B; Hospitals; Hour; Household; Housekeeping; Human; Immune system; In Vitro; Industry; Infection; Infection prevention; Intervention; Investments; Left; Legal patent; Licensing; Life; Magnetism; Marketing; Measures; Mechanics; Medical; Medical Surveillance; Medicine; Metabolic Marker; Methods; Microbe; Microbiology; Modern Medicine; Modification; Morbidity - disease rate; New York; None or Not Applicable; Nosocomial Infections; Numbers; Oxygen; Ozone; Pathologist; Patients; Persons; Phase; Pik-off; Plasma; Platelet Transfusion; Price; Principal Investigator; Process; Proteins; Public Health; Purpose; Quality of life; Quebec; Radiation therapy; Range; Rate; Reading; Reagent; Research; Research Project Grants; Residual state; Resources; Retrieval; Risk; Safety; Sales; Sampling; Savings; Scientist; Screening procedure; Seasons; Secure; Seeds; Sepsis; Series; Services; Side; Silver; Silver Compounds; Small Business Funding Mechanisms; Small Business Innovation Research Grant; Solutions; Solvents; Standards of Weights and Measures; Sterilization for infection control; Supporting Cell; Surface; Surgical incisions; System; T-Cell Leukemia; Techniques; Technology; Temperature; Testing; Texas; Time; Today; Transfusion; United States; United States Food and Drug Administration; United States National Institutes of Health; Universities; University of Texas M D Anderson Cancer Center; Viral; Virus; Water; Whole Blood; Work; antimicrobial; authority; bactericide; base; catalyst; cell growth; chemotherapy; clinically significant; college; commercialization; cost; day; design; engineering design; experience; hazard; improved; innovation; laptop; microbial; mortality; nano; nanoparticle; nanosized; nanostructured; new technology; novel; particle; pathogen; prevent; professor; programs; prototype; rapid growth; research and development; research clinical testing; seal; sensor; size; success; transmission process; ultraviolet irradiation; volunteer

DESCRIPTION (provided by applicant): The goal of this Phase I project is to demonstrate the feasibility of combining the well known and accepted antimicrobial metallic silver compound with magnetic nanoparticles and perform preliminary evaluation of its efficacy in bacterial inactivation in cellular blood product, such as platelets. Lynntech, in collaboration with M.D. Anderson Cancer Center in Houston, TX and The University of New York at Binghamton, will synthesis these silver coated magnetic nanoparticles (Ag-MP), which can be completely retrieved from platelets after the bacterial inactivation process. Our preliminary data with bacteria spiked blood platelets and broth have shown that both Gram positive and negative bacteria as well as aerobic and anaerobic bacteria can be inactivated. According to the National Blood Data Resource Center, about 13.9 million units of whole blood are donated in the United States each year. The market for blood products is over $ 10 billion and growing. With more than 90 million units of blood donated world-wide every year, the need for methods to improve the safety of blood products is truly significant. The economic impact associated with the savings from infection prevention is also enormous (when cases are considered as nosocomial infections, the estimated annual cost range from $296 million to $2.3 billion). Blood platelets are very important in modern medicine; however, they are very prone to bacterial contamination and their short-term shelf-life. Bacterial contamination of platelets is the leading cause of mobility and mortality from a transfusion-transmitted infection. Bacterial contamination rates for platelets have been estimated to occur at a frequency of 1:2,000 - 1:3,000 platelet units. The risk of receiving a bacterially contaminated platelet is 50 to 250 times higher than the combined risk of transfusion- related infections from HIV, hepatitis B and C, and human T cell leukemia (HTLV I/II) viruses. New compounds developed to counter microbial contamination in blood components have been developed and showed slight efficacy in deterring infections; however, these methods employ the addition of mutagenic and potentially carcinogenic chemicals that alter the genetic makeup of the microbes. Residual amounts of these chemicals can remain within the transfusion product and then be transfused. In some cases, these chemicals may interact with the product itself, potentially changing its character. The main objective of this Phase I is to develop a bactericide that will address the above challenges. This technology provides an opportunity for better management of the platelet supply affecting millions of Americans annually, specifically for preventing bacterial related infections and sepsis through transfusion of contaminated platelets. The economic impact is also enormous considering the market size and associated savings from prolonging platelet shelf life and improving infection prevention. Once developed, the product can also be expanded for use with other blood product components and other medical sterilization applications such as water sterilization, infected surgical incisions, trauma and burn wounds, etc.

描述（由申请人提供）：该阶段I项目的目的是证明将众所周知和接受的抗菌金属银化合物与磁性纳米颗粒相结合的可行性，并对其在细菌失活在细菌中的疗效进行初步评估，例如血小板。 Lynntech与德克萨斯州休斯敦的M.D. Anderson癌症中心合作，纽约宾厄姆顿大学将合成这些银色涂层的磁性纳米颗粒（AG-MP），在细菌失活过程后可以完全从血小板中完全检索。我们使用细菌尖刺的血小板和肉汤的初步数据表明，革兰氏阳性和阴性细菌以及有氧细菌和厌氧菌都可以被灭活。根据国家血液数据资源中心的数据，每年在美国捐赠了约1,390万单位的全血。血液产品市场超过100亿美元，增长。每年在全球范围内捐赠了超过9000万单位的血液，因此需要改善血液产品安全性的方法确实很重要。与预防感染节省相关的经济影响也是巨大的（当病例被认为是医院感染时，估计的年成本从2.96亿美元到23亿美元不等）。血小板在现代医学中非常重要。但是，它们非常容易受到细菌污染及其短期保质期。血小板的细菌污染是输血传播感染引起的流动性和死亡率的主要原因。据估计，血小板的细菌污染率以1：2,000-1：3,000血小板单位的频率发生。接受细菌污染的血小板的风险比HIV，乙型肝炎和C的输血相关感染的综合风险高50至250倍，以及人T细胞白血病（HTLV I/II）病毒。已经开发出来针对血液成分中的微生物污染而开发的新化合物，并在阻止感染中显示出轻微的功效。但是，这些方法采用了诱变和潜在的致癌化学物质的添加，这些化学物质会改变微生物的遗传构成。这些化学物质的剩余量可以保留在输血产品中，然后被输血。在某些情况下，这些化学物质可能与产品本身相互作用，可能会改变其特征。该阶段I的主要目的是开发一种将解决上述挑战的杀菌剂。这项技术为更好地管理血小板供应提供了机会，每年都会影响数百万美国人，特别是通过输注受污染的血小板来预防细菌相关感染和败血症。考虑到延长血小板保质期和改善预防感染的市场规模和相关节省的市场规模以及相关的节省，经济影响也巨大。一旦开发，该产品还可以扩展，以与其他血液产品组件以及其他医疗灭菌应用（例如水灭菌，感染手术切口，创伤和烧伤伤口）一起使用。

项目成果

Bacterial inactivation using silver-coated magnetic nanoparticles as functional antimicrobial agents.

• DOI: 10.1021/ac202164p
• 发表时间: 2011-11-15
• 期刊: ANALYTICAL CHEMISTRY
• 影响因子: 7.4
• 作者: Wang, Lingyan;Luo, Jin;Shan, Shiyao;Crew, Elizabeth;Yin, Jun;Zhong, Chuan-Jian;Wallek, Brandi;Wong, Season S. S.
• 通讯作者: Wong, Season S. S.